Navigation Links
Topokine Therapeutics Secures Financing from Schooner Capital to Advance Clinical Development of XAF5 Gel
Date:1/22/2013

NEWTON, Mass., Jan. 22, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics, a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, has announced a financing arrangement with Schooner Capital, a Boston-based investment firm.  The agreement provides Topokine with immediate capital and the ability to draw additional capital to advance the Company's pipeline, including XAF5 Gel, a clinical-stage skin cream for local reduction of excess subcutaneous fat.  Specific terms were not disclosed.

"We are delighted to partner with Schooner Capital," said Murat Kalayoglu, MD, PhD, Topokine President and CEO.  "Schooner's long-term commitment allows us to invest not only in the development of XAF5 Gel, but also other drugs in our pipeline."

"Topokine is generating impressive results and intellectual property at a rapid pace," said Ted Henderson , a Managing Director at Schooner Capital.  "We are committed to seeing Topokine's products get to market, whether by organic growth or with a best-in-class Pharmaceutical partner."

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics. The company's lead program, XAF5 Gel, is a skin cream being developed for local reduction of excess subcutaneous fat. XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. XAF5 reduces adipose tissue in vivo without inflammation or necrosis.

About Schooner Capital

Founded in 1971, Schooner Capital is a Boston-based private investment firm.  The firm approaches all investments with a long-term perspective and invests in private companies across stage and sector, with a focus on quality of management, unit economics, and long-term growth prospects.

Forward-Looking Statements

This press release contains forward-looking statements. These statements are based on current beliefs and expectations, but actual results may differ.

Media Contact: Murat Kalayoglu Topokine Therapeutics, Inc., 1.000.000.0000, murat.kalayoglu@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
2. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
3. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
4. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
5. Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics
6. Northwest Biotherapeutics Announces Public Offering of Common Stock and Warrants, and Listing on NASDAQ
7. PTC Therapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Ataluren in Duchenne Muscular Dystrophy
8. Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
9. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
10. Flexion Therapeutics Secures $20 Million in Series B Financing
11. Echo Therapeutics Announces Proposed Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
(Date:8/4/2017)... -- The search for test results that can be ... long been the goal of healthcare providers and the ... largest meeting of lab professionals and IVD firms this ... Kalorama Information.  The firm said scores of companies with ... and software were at the American Association for Clinical ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup for ... health IT to create efficiencies in healthcare information exchange and a trusted advisor to ... Forum which featured keynote addresses by Donald W. Rucker, MD, head of the ...
(Date:8/23/2017)... ... ... Nightingale College continues the semiannual Give Back Day tradition for its fourth year ... serving and volunteering for organizations that provide indispensable resources to the community. The College ... little extra help. , The College’s Give Back Day initiative began in 2013 ...
(Date:8/23/2017)... Elkhart, Indiana (PRWEB) , ... August 23, 2017 ... ... Whitney Boling, MD , has returned home to Indiana, and is now ... Boling is a board-eligible ophthalmologist that specializes in the diagnosis and treatment of ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC ... Awards® - for Risk Management Solution Innovations and Security Solution for Government Innovations. ... released in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , ...
(Date:8/22/2017)... ... 22, 2017 , ... The Women’s Choice Award, a growing platform that gives ... 2017 Women’s Choice Award. The identification by women of an effective new migraine ... sufferers are women. In a survey taken by the Women’s Choice Award organization, nine ...
Breaking Medicine News(10 mins):